A Clinical Case of Bulevirtide Therapy for Chronic HDV-Infection

Abstract

Background. The Republic of Sakha (Yakutia) is an endemic region for chronic hepatitis D, where the detection rate of antibodies to the delta virus is 35% [3]. The urgency of the problem of HDV infection is also determined by its aggressive and rapidly progressive course. In 2019, Bulevirtide, a drug for the treatment of chronic delta hepatitis, was registered in Russia. Three randomized trials showed a high rate of virological, biochemical response, as well as good tolerability and safety. Objective – to evaluate the efficacy and safety of Bulevirtide in the treatment of chronic HDV infection. Material and methods. A clinical case of a patient L. suffering from a chronic form of HDV infection receiving antiviral therapy is presented. Results. Bulevirtide demonstrated high efficacy, as evidenced by the development of a virological response during the first 14 weeks of therapy and a decrease in HDV RNA to an undetectable level within 29. Conclusions. It is necessary to widely introduce Bulevirtide for the treatment of patients with chronic delta hepatitis due to its high efficacy and safety.